Biopharmaceutical Industry Leaders Call for Principled Approach to COVID-19 Vaccines and Therapies

In a letter to the biopharmaceutical industry, CEOs from Ovid Therapeutics, Nkarta Therapeutics, Global Blood Therapeutics, Biotechnology Innovation Organization, Acorda Therapeutics, GlycoMimetics, Alnylam Pharmaceuticals, and Alkermes released a list of five principles they assert the industry should follow to ensure the effective assessment of data and evaluation of efficacy regarding COVID-19 therapies and vaccines. The principles include:

• Conducting clinical trials in adherence to best practices
• Publishing data in peer-reviewed journals or respected scientific sources, not press releases
• Ensuring the United States Food and Drug Administration remains a non-political regulatory body free from outside influence
• Introducing new therapies only when sufficient data support their use
• Eliminating the politicization of COVID-19 therapies and vaccines

Read the letter here.